As of June 21, 2025, Catalyst Biosciences Inc (CBIO) reports a EV/EBITDA of -0.27.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Catalyst Biosciences Inc's EV/EBITDA to Peers
To better understand Catalyst Biosciences Inc's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Catalyst Biosciences Inc (CBIO) | -0.27 |
| GlycoMimetics Inc (GLYC) | 77.25 |
| Abbvie Inc (ABBV) | 17.90 |
| Amgen Inc (AMGN) | 15.21 |
| Regeneron Pharmaceuticals Inc (REGN) | 12.54 |
| Gilead Sciences Inc (GILD) | 9.30 |
Compared to its competitors, Catalyst Biosciences Inc's EV/EBITDA is about average compared to peers, indicating market valuation in line with industry expectations.